Updates in Targeted Therapies for ALK+ and ROS1+ NSCLC from ESMO 2024 - Episode 3
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Related Content: